Our decision to restrict downstream qRT-PCR to A549 was deliberate and grounded in translational relevance: gefitinib is an EGFR tyrosine-kinase inhibitor used primarily in NSCLC, whereas data supporting routine use in TNBC are limited and context-dependent. Here, EGFR is linked to non-small cell lung carcinoma.